key: cord-0950055-8nu2ebyg authors: Grobben, M.; van der Straten, K.; Brouwer, P. J. M.; Brinkkemper, M.; Maisonnasse, P.; Dereuddre-Bosquet, N.; Burger, J. A.; Poniman, M.; Oomen, M.; Eggink, D.; Bijl, T. P. L.; van Willigen, H. D. G.; Wynberg, E.; Verkaik, B. J.; Figaroa, O. J. A.; de Vries, P. J.; Boertien, T. M.; Le Grand, R.; de Jong, M. D.; Prins, M.; Chung, A. W.; de Bree, G. J.; Sanders, R. W.; van Gils, M. J. title: Cross-reactive antibodies after SARS-CoV-2 infection and vaccination date: 2021-06-02 journal: nan DOI: 10.1101/2021.05.26.21256092 sha: 4b01a1c910a3c3b3f71ca2c1bf0fb39a3913fbb8 doc_id: 950055 cord_uid: 8nu2ebyg Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11 to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2 to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 S protein immunization in macaques, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine. One and a half year after the emergence of Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus infectious disease 2019 (COVID-19), the pandemic is still a major global issue with unprecedented consequences on healthcare systems and economies. Following the rapid initiation of many vaccine studies, the first vaccines are already FDA/EMA approved and mass vaccination campaigns are rolled out to hopefully soon subdue this pandemic 1-4 . However, these vaccines might have reduced efficacy against emerging SARS-CoV-2 variants, as was already shown for several approved vaccines when tested for safety and effectiveness against the B1.351 (501Y.V2) SARS-CoV-2 variant which is currently dominating the epidemic in South Africa 5, 6, 7 . To anticipate emerging variants, more broadly protective SARS-CoV-2 vaccines are desirable. However, the ultimate goal should be a pan-coronavirus vaccine, which would be able to induce broad immunity and protection against multiple coronaviruses, thereby preparing us for future outbreaks. New coronaviruses that infect humans (hCoVs) emerge frequently and SARS-CoV-2 is the fifth to be discovered in less than two decades, bringing the total up to seven 8 . These include the seasonal betacoronaviruses hCoV-OC43 and hCoV-HKU1 as well as alphacoronaviruses hCoV-NL63 and hCoV-229E, which usually cause mild respiratory symptoms and account for approximately 5-30% of common colds during the winter season 9, 10 The majority of SARS-CoV-2 vaccines are based on the Spike (S) glycoprotein, a homotrimeric glycoprotein that is present on the surface of all coronaviruses and is the main target of protective antibodies. The S protein plays a pivotal role in viral entry and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint consists of an S1 subdomain including the receptor binding domain (RBD) and an S2 subdomain containing the fusion peptide 14, 15 . The S protein of SARS-CoV-2 is most closely related to the S protein of SARS-CoV (~75% amino acid sequence identity), shows less similarity to MERS-CoV S protein (~50% identity) and is more distinct from the S proteins of the seasonal hCoVs (~25-30% identity) 16, 17 . Although this sequence identity is considered low from the perspective of eliciting cross-reactive antibodies by vaccination, several studies observed cross-reactivity of COVID-19 sera against other hCoVs [18] [19] [20] [21] [22] . In addition, the isolation and engineering of broader hCoV monoclonal antibodies has been reported [23] [24] [25] . In this study, we identify broad hCoV antibody responses following SARS-CoV-2 infection and vaccination. We identify the S2 subdomain as a prominent target for cross-reactive antibodies and demonstrate that cynomolgus macaques vaccinated with a SARS-CoV-2 S protein nanoparticle vaccine elicit detectable antibody responses to other hCoVs. These results will guide the development of a pancoronavirus vaccine. Sera from 50 PCR confirmed SARS-CoV-2 infected patients, aged 22 to 75 years, who suffered from a range of COVID-19 disease severities were obtained 4-6 weeks after symptom onset (Supplementary Table 1 ). A custom Luminex assay was used to measure IgG antibody levels to the pre-fusion stabilized trimeric SARS-CoV-2 spike (S) protein in these convalescent COVID-19 sera and compared to pre-pandemic healthy donor sera. Sera from convalescent COVID-19 patients showed 990-fold higher antibody levels to SARS-CoV-2 S protein compared to pre-pandemic healthy donor sera (median 3.8 log10 vs. 0.8 log10 Median Fluorescent Intensity (MFI), p<0.0001) (Fig. 1a) . This is in line with a positive serological response in all but one of the participants using the commercially available WANTAI SARS-CoV-2 RBD total Immunoglobulin serum ELISA ( Fig. 1a and Supplementary Table 1 ). When subdividing the convalescent . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint patients based on admission status, 4-fold higher antibody levels were observed for hospitalized patients compared to non-hospitalized patients (median 4.1 log10 vs. 3.5 log10 MFI, p<0.0001). SARS-CoV-2 neutralization capacity was also significantly higher (5-fold) in hospitalized patients (3.6 log10 vs. 2.9 log10 MFI, p<0.0001) and antibody levels and neutralization capacity were strongly correlated in all patients (Spearman r = 0.735, p<0.0001) (Fig. 1b ). An 8-fold higher antibody response to the SARS-CoV-2 S protein was observed in the oldest age group of COVID-19 patients (age > 60) compared to the youngest age group (age < 35) (4.1 log10 vs. 3.2 log10 MFI, p<0.001), which is in line with age being a risk factor for severe COVID-19 (Fig. 1a) 26 . No difference in antibody levels was observed between sex (p=0.71 Mann-Whitney U test). These findings were confirmed with a principal component analysis, which showed two distinct groups based on hospital admission status, and indicated age as an important contributing variable (Fig. 1c, Supplementary Fig. 1 ). Overall, these results are consistent with previous studies 27,28,29 . Next, we measured IgG binding to the S proteins of other hCoVs: SARS-CoV, MERS-CoV, hCoV-OC43, hCoV-HKU1, hCoV-229E and hCoV-NL63. We found significantly higher levels of antibodies binding to all hCoV S proteins in convalescent COVID-19 sera compared to pre-pandemic healthy donor sera, with the largest difference for SARS-CoV and MERS-CoV S protein (123 and 11-fold difference between medians, respectively) (Fig. 2a) . For the circulating seasonal hCoVs, a 2 to 4-fold difference in median levels of antibodies binding to the S proteins was observed; hCoV-OC43 (4.2fold, p<0.0001), hCoV-HKU1 (4.3-fold, p<0.0001), hCoV-229E (3.8-fold, p<0.0001) and hCoV-NL63 (1.8-fold, p<0.01). No such difference was found for the control protein Tetanus toxoid (0.8-fold, p=0.85) ( Supplementary Fig. 2a) . To further explore the specificity of the cross-reactive antibodies in convalescent COVID-19 sera, we performed a depletion with soluble SARS-CoV-2 S protein ( Fig. 2b and Supplementary Fig. 3 ). Depletion of convalescent COVID-19 sera resulted in a 92% reduction of antibody levels against the SARS-CoV-2 S protein. The reduction of antibodies binding to the other hCoV S proteins was strongest for SARS-CoV (61% mean reduction) and MERS-CoV (25%). A more modest reduction of signal was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint observed for hCoV-OC43 (13% mean reduction) and hCoV-229E S protein (6%) and we observed no depletion of antibodies binding to hCoV-HKU1 (2%) and hCoV-NL63 (-2%). On the individual level, some patients showed up to 72%, 70% and 34% reduction of antibodies binding to hCoV-OC43, hCoV-229E and hCoV-HKU1 S protein after depletion, respectively. No reduction in signal was observed for the control protein Tetanus toxoid after SARS-CoV-2 S depletion (Fig. 2b, Supplementary Fig. 2b ). Antibodies binding to other hCoV S proteins in pre-pandemic healthy donor sera did not decrease after depletion ( Supplementary Fig. 2c ). These depletion experiments corroborate the finding that convalescent COVID-19 sera contain crossreactive antibodies able to recognize other hCoV S proteins. We observed the highest cross-reactivity for the more closely related hCoVs (Supplementary Table 3) . Indeed, the level of cross-reactivity expressed as the reduction of binding antibodies after depletion by SARS-CoV-2 S protein was associated with the level of sequence identity (Spearman r=0.83, p=0.06) ( Supplementary Fig. 4 ). To further explore the possible functionality of these cross-reactive antibodies, we investigated the correlation between hCoV S protein binding antibodies and SARS-CoV-2 neutralization titers. In addition to the observed correlation between SARS-CoV-2 S protein antibody levels and SARS-CoV-2 neutralization, we found a moderate correlation between SARS-CoV-2 neutralization and antibodies binding to SARS-CoV S protein (r = 0.545, P<0.0001), a weak correlation with antibodies that bind to MERS-CoV, hCoV-HKU1 and hCoV-229E S protein (r = 0.324, 0.308, 0.320 respectively, all p <0.05) and no correlation with antibodies binding to hCoV-OC43 and hCoV-NL63 S protein (r = 0.188 and -0.095, p >0.05) ( Supplementary Fig. 6 ). These correlations suggest that cross-reactive antibodies form a minor component of the neutralizing antibodies induced by SARS-CoV-2 infection. We also investigated if there was an association between cross-reactivity and disease severity with a principal component analysis. Antibodies binding to other hCoV S proteins did not contribute to the separation between patients based on admission status as clearly as was seen for SARS-CoV-2 S protein antibody levels, suggesting a limited impact of cross-reactive antibodies on disease severity ( Supplementary Fig. 5 ). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. To determine the main target on the SARS-CoV-2 S protein for cross-reactive antibodies, we performed a depletion experiment in which we compared the reduction of IgG binding to hCoV S proteins after depleting the sera with soluble SARS-CoV-2 S1 or S2 subdomains. After depletion with the SARS-CoV-2 S2 subdomain, a 48%, 20% and 19% mean reduction of signal was observed for antibodies binding to SARS-CoV, MERS-CoV, and hCoV-OC43 S protein, respectively, while no reduction was observed after S1 depletion (Fig. 3) . Absolute MFI values before and after depletion are shown in Supplementary Fig. 7a . For some individuals, depletion rates reached up to 83% for SARS-CoV, 75% for MERS-CoV and 80% for hCoV-OC43 S protein while there were no individuals with substantial reduction of cross-reactive antibodies after S1 depletion. We did not observe significant depletion of antibodies binding to hCoV-HKU1 and hCoV-229E S proteins by S1 or S2 subdomains of SARS-CoV-2 at the group level. However, in some individuals the signal was reduced by up to 59% for hCoV-HKU1 and 71% for hCoV-229E S protein following depletion with the SARS-CoV-2 S2 subdomain, while such effects were not observed after S1 subdomain depletion. Changes in antibodies that bind to hCoV-NL63 S protein after depletion with SARS-CoV-2 S1 and S2 subdomains were comparable to those observed with the control protein Tetanus toxoid and to the reduction in signal for hCoV S in healthy donors (Supplementary Fig. 3 and 7) . SARS-CoV-2 S2 subdomain depletion was significantly correlated with S2 sequence identity (r = 0.90, p = 0.03) while there was no correlation for SARS-CoV-2 S1 subdomain depletion (r = 0.23, p = 0.67) ( Supplementary Fig. 4 ). These results indicate that S2-specific antibodies have a greater contribution to cross-reactivity than S1-specific antibodies, which is in accordance with the higher conservation of the S2 subdomain compared to the S1 subdomain (Supplementary Table 2 ) 30 . The observed cross-reactive antibody response following natural infection with SARS-CoV-2 does not reveal whether these might be de novo responses or the result of cross-boosted pre-existing memory from previous hCoV infections. To investigate the ability of SARS-CoV-2 vaccination to induce de novo cross-reactive antibodies against hCoVs, we investigated the serum of six cynomolgus macaques which were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint vaccinated three times with pre-fusion stabilized trimeric SARS-CoV-2 S protein coupled to I53-50 nanoparticles 31 . The vaccination response was studied by comparing serum IgG binding to hCoV S proteins after three vaccinations (week 12) to the pre-immunization baseline (week 0). We observed that all macaques developed detectable antibodies that bind to all hCoV S proteins. Antibodies binding to SARS-CoV, MERS-CoV and hCoV-OC43 S proteins were increased compared to baseline by 3313-, 168-, and 106-fold, respectively (Fig. 4a) . This cross-reactivity was already detectable two weeks after the first immunization ( Supplementary Fig. 8a ). The induction of antibodies that bind to hCoV-HKU1 and hCoV-229E S proteins was relatively low with a 39-and 16-fold increase from baseline, respectively. Antibodies binding to hCoV-NL63 S protein showed only a 6-fold increase from baseline and there was no increase observed for Tetanus toxoid ( Fig. 4a and Supplementary Fig. 8b and c). All comparisons were statistically significant except for the Tetanus toxoid. Using the SARS-CoV-2 S protein depletion assay, a 79%, 98% and 99% mean reduction of antibodies binding to SARS-CoV, MERS-CoV and hCoV-OC43 S protein, respectively, was observed (Fig. 4b ). In addition, depletion also resulted in a mean reduction of antibodies binding to proteins hCoV-229E S (92%), hCoV-HKU1 S (92%) and hCoV-NL63 S (75%). Virtually no depletion (3%) was observed for the control protein Tetanus toxoid ( Supplementary Fig. 9 ). Together, these results demonstrate that the SARS-CoV-2 S protein is capable of inducing cross-reactive antibodies to both alpha and beta hCoVs, in macaques that we assume have no pre-existing hCoV immunity. As mass vaccination campaigns take place around the globe, there is optimism that the SARS-CoV-2 pandemic will be subdued. However, there will likely be future challenges with emerging SARS-CoV-2 variants as well as with entirely new hCoVs. vaccines have substantially reduced activity against some SARS-CoV-2 variants 3,32,33,34 . Therefore, development of broader SARS-CoV-2 vaccines is needed, with a pan-coronavirus vaccine as the ultimate goal. In this study, we show that convalescent COVID-19 sera have higher levels of antibodies that bind to other hCoV S proteins compared to pre-pandemic healthy . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint donors. We confirmed this cross-reactivity by showing that SARS-CoV-2 S protein could partially deplete antibodies binding to all hCoV S proteins except hCoV-NL63 in COVID-19 patient sera, while no effect of SARS-CoV-2 S protein depletion was observed in healthy donor sera. Additionally, we see that the elevation of hCoV S antibody levels and the capacity of SARS-CoV-2 S protein to deplete these antibodies is highest for hCoV S proteins that share most sequence homology with the SARS- As we show that most of the cross-reactivity is targeting the S2 subdomain of the S protein, we propose that this subdomain should receive more attention in vaccine design. Interestingly, although most neutralizing antibodies target the S1 subdomain including the RBD, protective neutralizing antibodies targeting the S2 subdomain have also been identified 41 . Furthermore, analogous to some influenza virus hemagglutinin . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. The results from this study on the presence and specificity of cross-reactive antibodies to other hCoVs after SARS-CoV-2 infection and vaccination, emphasize the feasibility of broad coronavirus vaccines and may guide future vaccine designs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Sera of 50 SARS-CoV-2 infected adults were collected 4-6 weeks after symptom onset through the cross-sectional COVID-19 Specific Antibodies (COSCA) study (NL 73281 .018.20) as described previously 46 . In short, all participants had at least one A prefusion stabilized S protein ectodomain of SARS-CoV-2 and SARS-CoV with a T4 trimerization domain and hexahistidine (His) tag were previously described 46 . A . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint prefusion stabilized S protein ectodomains construct of hCoV-HKU1 was designed as described previously 47 . Specifically, a gene encoding amino acids 1-1276, in which the furin cleavage site (amino acids 752-756) was replaced with a GGSGS sequence and amino acids at position 1067 and 1068 were mutated to prolines, was ordered and cloned into a pPPI4 plasmid containing a T4 trimerization domain followed by a hexahistidine tag. The same procedure was used to generate prefusion stabilized S Resulting protein concentrations were determined using a Nanodrop 2000 Spectrophotometer and proteins were stored at -80°C until needed. Proteins were covalently coupled to Luminex Magplex beads using a two-step carbodiimide reaction and a ratio of 75 µg protein to 12.5 million beads for SARS-CoV- Finally, the beads were washed and stored at 4°C in PBS containing 0.05% Sodium Azide and used within six months. Detection of the His tag on each S protein-coupled bead was used to confirm the amount of protein on the beads. Optimization experiments determined the optimal concentration for detection of hCoV S protein binding antibodies to be 1:10,000 dilution for COVID-19 patients, 1:50,000 for SARS-CoV and SARS-CoV-2 detection in cynomolgus macaques and 1:500 for detection of binding antibodies to other hCoV S proteins in cynomolgus macaques. 50 µL of a working bead mixture containing 20 beads per µl of each region was incubated overnight with 50 µl of diluted serum. Plates were sealed and incubated on a plate shaker overnight at 4°C. The next day, plates were washed with TBS containing 0.05% Tween-20 (TBST) using a hand-held magnetic separator. Beads were resuspended in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Assays were performed twice with similar results (Supplementary Fig. 9 ). Convalescent COVID-19 patient sera were diluted 1:10,000 with addition of 10 µg/mL soluble recombinant SARS-CoV-2 pre-fusion stabilized S protein, S1 or S2 subdomain (ABclonal Biotechnology) or without protein (as undepleted controls). Immunized macaque sera were diluted 1:500 with addition of 30 µg/mL SARS-CoV-2 S protein. Incubation was performed in uncoated 96-wells plates on a shaker at room temperature for 1 h. Then, 50 µl of a working bead mixture containing 20 beads per µl of each region was added and the plates were incubated 2 h on a shaker at room temperature. After 2 h, the above described Luminex protocol was continued starting with the TBST washes and the Goat-anti-human IgG-PE incubation. The pseudovirus neutralization assay was performed as described previously 31 . Briefly, HEK293T cells expressing the SARS-CoV-2 receptor ACE2 were seeded in poly-L-lysine coated 96-wells plates and the next day triplicate serial dilutions of heatinactivated serum samples were prepared, mixed 1:1 with SARS-CoV-2 pseudovirus, incubated for 1 h at 37°C and then added in a 1:1 ratio to the cells. After 48 h, the cells were lysed, transferred to half-area 96-wells white microplates (Greiner Bio-One) and Luciferase activity was measured using the Nano-Glo Luciferase Assay System (Promega) with a Glomax system (Turner Biosystems). Relative luminescence units were normalized to the units from cells infected with pseudovirus in absence of serum. Neutralization titers (ID50) were the serum dilution at which infectivity was inhibited 50%. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Luminex data were log transformed prior to any statistical analysis. P values below 0.05 were considered statistically significant. Mann-Whitney U-tests for unpaired comparisons, Wilcoxon matched-pairs signed rank test for paired comparisons and Spearman correlations were performed in GraphPad Prism 8.3.0. Principal component analysis was performed in Matlab 9.6 (R2019a). Data supporting the findings in this manuscript are available from the corresponding author upon request. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. We are thankful to the participants of the COSCA-study for their contribution to this research. In addition, we thank the research team of the RECoVERD/VIS-cohort study for assisting with the recruitment and inclusion of participants. We thank Gestur The authors declare no competing interests. after SARS-CoV-2 S1 and S2 depletion is shown in Supplementary Fig 3a. The percent decrease of IgG binding to hCoV S and Tetanus toxoid protein in healthy donor sera after SARS-CoV-2 S1 and S2 depletion is shown in Supplementary Fig. 7b and c. All MFI values are shown in Supplementary Fig. 3a and 7a . MFI = Median Fluorescent Intensity, S = spike protein. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint The correlation between S protein (a), S1 subdomain (b) and S2 subdomain (c) sequence identity of SARS-CoV-2 with the different hCoV S proteins (also shown in Supplementary Table 2 ) and the reduction of antibodies binding to hCoV S proteins in the SARS-CoV-2 S protein depletion assay (also shown in Figure 2b ) was determined using Spearman correlation. S = spike protein, r = Spearman's rank correlation coefficient. The correlation between the SARS-CoV-2 pseudovirus neutralization (also shown in is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint healthy donors (n = 30) after depletion with soluble recombinant SARS-CoV-2 S protein, S1 subdomain and S2 subdomain. Box plots range the minimum and maximum values. -= undepleted sera, S = trimeric S protein depleted sera, S1 = S1 subdomain depleted sera, S2 = S2 subdomain depleted sera. (B) Percent decrease of IgG binding to hCoV S proteins in sera of healthy donors (n = 30) after depletion with soluble recombinant SARS-CoV-2 S1 subdomain or S2 subdomain. (C) Percent decrease of IgG binding to Tetanus toxoid control protein in sera of healthy donors (n = 30) after depletion with soluble recombinant SARS-CoV-2 S1 subdomain or S2 The reproducibility of the custom Luminex assay is shown by plotting data from two independent assays performed on different days with the same samples. The data on the Y axis is found in Fig. 3 and the data on the X axis is also found in Fig. 1 and 2 . The quality of the replicates is presented by the R 2 and slope of a simple linear regression performed on the log10 transformed MFI data. MFI = median fluorescent intensity, S = spike protein, N = nucleocapsid, RBD = receptor binding domain. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Fig. 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Fig. 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Fig. 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Fig. 4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 2, 2021. ; https://doi.org/10.1101/2021.05.26.21256092 doi: medRxiv preprint Safety and Efficacy of the BNT162b2 mRNA Covid-19 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Interim Results of a Phase 1-2a Trial of Ad26 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Pandemic moves and countermoves: vaccines and viral variants